[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342589-105":59,"doc-detail-342589-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","weakened-apcc-activity-at-mitotic-exit-drives-cancer-vulnerability-to-kif18a-inhibition","Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition","","Efficacy of current antimitotic cancer drugs is constrained by toxicity to highly proliferative healthy tissues. This work identifies a cancer-specific dependency on the microtubule motor protein KIF18A as a therapeutic opportunity. However, only certain cancers rely on KIF18A, and the determinants remain unclear. Results show that KIF18A inhibition triggers widespread, modest increases in spindle assembly checkpoint signaling from kinetochores, causing lethal mitotic delays. Sensitivity is linked to weak basal APC/C activity and persistent metaphase SAC signaling, revealing SAC:APC/C imbalance hallmarks and exploitable vulnerabilities in cancer cell division.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/weakened-apcc-activity-at-mitotic-exit-drives-cancer-vulnerability-to-kif18a-inhibition/342589/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/weakened-apcc-activity-at-mitotic-exit-drives-cancer-vulnerability-to-kif18a-inhibition/342589.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KIF18A considered an attractive cancer therapy target?","Question",{"text":112,"@type":113},"KIF18A dependency is cancer-specific and involves the microtubule motor protein that helps regulate mitosis, making its inhibition a potential therapeutic strategy with a mechanism distinct from broadly cytotoxic antimitotic drugs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does KIF18A inhibition do to spindle assembly checkpoint (SAC) signaling?",{"text":117,"@type":113},"KIF18A inhibition produces a modest but widespread increase in SAC signaling originating from kinetochores, which can lead to lethal delays during mitosis.",{"name":119,"@type":110,"acceptedAnswer":120},"What cellular conditions make cells particularly sensitive to KIF18A inhibition?",{"text":121,"@type":113},"Sensitivity is associated with robustness of the metaphase-to-anaphase transition, and with weak basal APC/C activity and/or persistent SAC signaling through metaphase.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342589,1790623639,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Article  \nWeakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition  \nColin R Gliech 1, Zhong Y Yeow1, Daniel Tapias-Gomez1, Yuchen Yang 1, Zhaoyu Huang1,  \nAndréa E Tijhuis 2, Diana CJ Spierings 2, Floris Foijer 2, Grace Chung3, Nuria Tamayo 4, Zahra Bahrami-Nejad5, Patrick Collins5, Thong T Nguyen5, Andres Plata Stapper 6, Paul E Hughes 3, Marc Payton3 & Andrew J Holland 1 ✉  \nAbstract  \nThe efﬁcacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative healthy tissues. A cancer-speciﬁc dependency on the microtubule motor protein KIF18A therefore makes it an attractive therapeutic target. Not all cancers require KIF18A, however, and the determinants underlying this distinction remain unclear. Here, we show that KIF18A inhibition drives a modest and widespread increase in spindle assembly checkpoint (SAC) signaling from kinetochores which can result in lethal mitotic delays. Whether cells arrest in mitosis depends on the robustness of the metaphase-to-anaphase transition, and cells predisposed with weak basal anaphase-promoting complex/cyclosome (APC/C) activity and/or persistent SAC signaling through metaphase are uniquely sensitive to KIF18A inhibition. KIF18Adependent cancer cells exhibit hallmarks of this SAC:APC/C imbalance, including a long metaphase-to-anaphase transition, and slow mitosis overall. Together, our data reveal vulnerabilities in the cell division apparatus of cancer cells that can be exploited for therapeutic beneﬁt.  \nKeywords Anaphase Promoting Complex (APC/C); Cancer; KIF18A; Mitosis; Spindle Assembly Checkpoint (SAC)  \nSubject Categories Cancer; Cell Cycle  \n[https://doi.org/10.1038/s44318-024-00031-6](https://doi.org/10.1038/s44318-024-00031-6)  \nReceived 1 May 2023; Revised 23 December 2023; Accepted 2 January 2024  \nPublished online: 26 January 2024  \nIntroduction  \nCancer is characterized by uncontrolled cell growth. Consequently, the cell cycle and mitosis have long been appealing targets for chemotherapy. Early successes with “antimitotic” drugs emerged from using microtubule targeting agents such as taxanes and vinca alkaloids to disrupt the assembly of the mitotic spindle apparatus  \nand kill dividing cells (Checchi et al, 2003; Jordan and Wilson, 2004) . Despite decades of widespread usage and efﬁcacy across several tumor types, these drugs suffer from signiﬁcant limitations: antimitotic drugs also kill healthy, highly proliferative cells of the bone marrow and gut, and signiﬁcant neurotoxicity is observed due to the disruption of microtubule dynamics in nondividing neurons (Čermák et al, 2020; Gornstein and Schwarz, 2014; Klein and Lehmann, 2021; Marupudi et al, 2007; Shemesh and Spira, 2009) . These drawbacks fueled the development of a new class of drugs that target essential mitotic proteins such as kinases and microtubule motor proteins. This second generation of antimitotic agents mitigates the neurotoxicity observed with microtubule targeting agents. However, myelosuppression remains a doselimiting toxicity in patients (Chan et al, 2012; Serrano-del Valle et al, 2021), and as a result, these drugs have so far failed to progress in the clinic.  \nBecause antimitotic agents agnostically kill all dividing cells, identifying and exploiting tumor-speciﬁc vulnerabilities in the cell division apparatus remains a major opportunity for drug development. One promising target is the plus-end-directed motor protein KIF18A, which is uniquely essential for the division of certain cancers (Cohen-Sharir et al, 2021; Marquis et al, 2021; Quinton et al, 2021) . KIF18A accumulates at the plus ends of kinetochore microtubules and suppresses chromosome oscillations within the metaphase plate (Du et al, 2010; Mayr et al, 2007; Stumpff et al, 2008; Zhu et al, 2005) . Loss of KIF18A disrupts chromosome alignment, leading to an increased instance of lagging anaphase chromosomes and micronucleation (Fonseca et al, 2019; Lin et al, 2020; Quinton et al, 20","cbCaihi595uTcTD0","https://ap.wps.com/l/cbCaihi595uTcTD0","pdf",23333943,29,"English","# Introduction\n## Antimitotic cancer drugs and limitations\n## Targeting tumor-specific vulnerabilities in cell division\n## Role of KIF18A in chromosome alignment and SAC","[{\"question\":\"Why is KIF18A considered an attractive cancer therapy target?\",\"answer\":\"KIF18A dependency is cancer-specific and involves the microtubule motor protein that helps regulate mitosis, making its inhibition a potential therapeutic strategy with a mechanism distinct from broadly cytotoxic antimitotic drugs.\"},{\"question\":\"What does KIF18A inhibition do to spindle assembly checkpoint (SAC) signaling?\",\"answer\":\"KIF18A inhibition produces a modest but widespread increase in SAC signaling originating from kinetochores, which can lead to lethal delays during mitosis.\"},{\"question\":\"What cellular conditions make cells particularly sensitive to KIF18A inhibition?\",\"answer\":\"Sensitivity is associated with robustness of the metaphase-to-anaphase transition, and with weak basal APC/C activity and/or persistent SAC signaling through metaphase.\"}]","Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition | PDF",1790047280,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0980fe0906aea05a33d397e5a1cdc196.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe6cd7871f3df4fd49911487081390fb.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f143eea1a9a800d2e5aefb3b64c1247.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3a9893720e17ba8b6b6d87b1eca2921.webp",980,1301]